Johns Hopkins Tests Deliberate Pacing Trick to Rescue Failing Hearts
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
20 articles
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
A 2025 review examines how methylene blue's nitric oxide inhibition can restore vascular tone in septic and vasoplegic shock patients.
A new framework combining rapid point-of-care fibrinogen testing, viscoelastic assays, and lab tests could eliminate preventable postpartum deaths.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.
Breakthrough anti-fibril depleters could revolutionize treatment for transthyretin amyloid cardiomyopathy, a deadly heart condition.
Sotatercept reduced dangerous pressure in heart failure patients' lungs and improved walking ability in phase 2 study.
A JAMA review synthesizes evidence showing CRT significantly reduces mortality and hospitalizations in heart failure patients with electrical dyssynchrony.
Novel medication lowers stubborn blood pressure by 5% and reduces kidney damage markers by 55% in patients with chronic kidney disease.
Breakthrough treatment works through multiple mechanisms beyond the lungs, enhancing oxygen delivery and muscle function.
UC San Diego scientists developed an injectable hydrogel that travels the bloodstream to reduce inflammation and regenerate damaged heart tissue.
SHR-1918 antibody dramatically reduced LDL cholesterol in patients with severe genetic hypercholesterolemia through novel pathway.
Small trial explores how amiloride improves oxygen delivery to heart muscle by enhancing potassium transport in red blood cells.
A decade of US data reveals persistent underuse of single-pill combination therapy for hypertension, despite its superiority for blood pressure control.
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
Meta-analysis shows recaticimab dramatically reduces LDL cholesterol and other cardiovascular risk markers with manageable side effects.
The DECISION trial finds low-dose digoxin did not significantly cut hospitalizations or cardiovascular death in 1,001 HFrEF/HFmrEF patients.
A comprehensive review outlines how early blood product administration and avoiding excess fluids can dramatically improve outcomes in obstetric hemorrhage.
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.